Diffuse Large B-Cell Lyphoma

The European Commission (EC) has granted conditional approval to Incyte Corporation (NASDAQ: INCY) - MorphoSys AG's (NASDAQ: MOR) Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval covers Minjuvi combined with...

Incyte Corporation (NASDAQ: INCY) and InnoCare have entered into a collaboration and license agreement to develop and commercial tafasitamab in Greater China. Under the terms of the agreement, InnoCare will pay $35 million upfront. Incyte is eligible to receive up to an...

Gilead Sciences Inc's (NASDAQ: GILD) unit Kite Pharma has announced top-line results from the primary analysis of ZUMA-7 of Yescarta (axicabtagene ciloleucel) compared to standard of care (SOC) in second-line relapsed or refractory large B-cell lymphoma (LBCL)....

BTIG’s Dane Leone has upgraded Juno Therapeutics Inc (NASDAQ: JUNO) to Neutral from Sell, as the shares have hit his target price and the ASH abstract release showed similar response rates for the company’s JCAR017 versus Kite Pharma Inc (NASDAQ: KITE)’s KTE-C19 in patients with...